Trial · NCT00763750
PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors
NCT00763750, Phase 2, Completed, howard safran; results first posted 2013-12-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors. Trials, record NCT00763750. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00763750
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors
- NCT number
- NCT00763750
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 25 participants, actual
- Lead sponsor
- howard safran
- Conditions
- Brain Tumor
- Interventions
- PPX +TMZ+XRT
- First posted
- 2008-10-01
- Last updated
- 2020-02-17
- Results first posted
- 2013-12-16
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients Assessed for Toxicity According to CTC Version 3.0 | Throughout the entire study until patient is removed from study an average of 6 weeks |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients Assessed for Toxicity According to CTC Version 3.0 | Throughout the entire study until patient is removed from study an average of 6 weeks | participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients Assessed for Toxicity According to CTC Version 3.0 | PPX +TMZ+XRT | 25 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | PPX +TMZ+XRT | 25 | |
| Overall Study | COMPLETED | PPX +TMZ+XRT | 25 | |
| Overall Study | NOT COMPLETED | PPX +TMZ+XRT | 0 |
Source ClinicalTrials.gov
Adverse events23
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | rash | Investigations | PPX +TMZ+XRT | 5 | 25 | 5 |
| other | infection normal ANC (thrush included) | Investigations | PPX +TMZ+XRT | 8 | 25 | 8 |
| other | fatigue | Investigations | PPX +TMZ+XRT | 7 | 25 | 7 |
| other | seizure | Investigations | PPX +TMZ+XRT | 3 | 25 | 3 |
| other | headache | Investigations | PPX +TMZ+XRT | 3 | 25 | 3 |
| other | insomnia | Investigations | PPX +TMZ+XRT | 2 | 25 | 2 |
| other | vomiting | Investigations | PPX +TMZ+XRT | 2 | 25 | 2 |
| other | Nausea | Investigations | PPX +TMZ+XRT | 2 | 25 | 2 |
| other | Alopecia | Investigations | PPX +TMZ+XRT | 4 | 25 | 4 |
| other | constipation | Investigations | PPX +TMZ+XRT | 3 | 25 | 3 |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | PPX +TMZ+XRT | ||
| Total, other adverse events | PPX +TMZ+XRT | 25 | 25 |
| Total, serious adverse events | PPX +TMZ+XRT | 6 | 25 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00763750
GET https://conductscience.org/api/trials/v1/NCT00763750/events?page=2